NJ-TRUE
True , the fastest-growing global platform of innovative talent management products and services, announced today it has appointed Kate Vanek as general manager, international. Kate joins True from BlackRock where she held the dual responsibility of CFO of EMEA and COO of global finance.
In her role, Kate will work closely with True’s global leadership to enhance and expand the firm’s international executive search business and broader platform of talent management products and services including Thrive, Synthesis, and AboveBoard. Kate is London-based and will oversee the international business across EMEA and APAC, which today includes True's offices in Amsterdam, Berlin, Dubai, London, Melbourne, Shanghai, Singapore, Stockholm, Sydney and Tel Aviv.
“Kate has a passion for talent management and a dynamic, inspirational leadership style,” said Joe Riggione , True co-founder and co-CEO. “She’s a high-performance operator who combines her personal and business experiences to connect people and complex global organizations. She is an impressive leader with an extraordinary track record, and we are lucky to have her.”
“I’m thrilled to be joining True during this period of expansion, and I’m excited to help propel True’s vision to build the global talent management firm of the future,” Kate commented. “True’s special culture and commitment to investing in its people, combined with their world-class executive search expertise and cutting-edge platform make it a place I couldn’t be more proud to join.”
“Kate's experience in strategic business building prepares her to expand our offerings globally to meet the needs of our clients who rely on True’s talent expertise and platform to help them grow and thrive,” said Brad Stadler , True co-founder and co-CEO.
Kate Vanek, True’s GM, International
Kate’s background has rich diversity of experience in finance, strategy and business operations, M&A, investor relations, DE&I initiatives, and leadership development. She has managed global teams in leadership roles across a range of industries from financial services, data science, consumer behavior measurement to industrials.
ABOUT TRUE
True is a platform of products and services driving the intelligence behind talent management:
True Search
Global recruitment for board members, c-suite executives, VPs, directors, and other strategic talent. We focus on investment firms, their portfolio companies and public companies seeking transformative growth.
Thrive
Collaborative, real-time talent relationship management software and information services for search firms, in-house recruiters and VC/PE firms looking to make better hiring decisions.
Synthesis
A multi-layered approach to leadership assessment and development, which combines the evaluation methods of elite military units, executive coaching techniques and agile methodology principles.
AboveBoard
True co-founded AboveBoard, a diversity-focused startup bringing unparalleled solutions to the critical need to bring more women and executives of color to leadership roles. With AboveBoard's two-way platform, members get unique visibility to hundreds of opportunities while companies get access to qualified candidates.
True Equity
True Equity provides exposure to high-quality venture capital and growth equity investments. As a value-added talent partner, True Equity makes direct investments alongside premier investors. True Equity Fund I participates in Series A and B investments. True Equity Growth Fund II focuses on late stage venture and growth equity companies.
Vera
Vera is a family of investment funds that backs exceptional entrepreneurs and companies dedicated to changing our collective future through technology at the pre-seed, seed, early, and late stages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005587/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom